Romana Shehzadi, MD
Gastroenterology · Federal Way, WANPI 1053509257
Payments from drug & device makers
Across 68 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$239
- Phathom Pharmaceuticals, Inc.$224
- Regeneron Healthcare Solutions, Inc.$148
- Madrigal Pharmaceuticals$135
- Aimmune Therapeutics, Inc.$134
- Johnson & Johnson$123
- plus $809 from 15 others
What the payments were for
- Food & beverage$1,811100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $239 |
| Phathom Pharmaceuticals, Inc. | 7 | $224 |
| Regeneron Healthcare Solutions, Inc. | 6 | $148 |
| Madrigal Pharmaceuticals | 5 | $135 |
| Aimmune Therapeutics, Inc. | 5 | $134 |
| Johnson & Johnson | 5 | $123 |
| Janssen Scientific Affairs, LLC | 1 | $109 |
| AbbVie | 5 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $96 |
| Sanofi | 3 | $86 |
| Lilly USA, LLC | 3 | $75 |
| Ipsen Biopharmaceuticals, Inc | 2 | $58 |
| Gilead | 2 | $53 |
| Celltrion USA Inc. | 2 | $51 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Pfizer | 2 | $35 |
| Organon | 1 | $26 |
| Novo Nordisk | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Biocon Biologics Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,811 in reported general payments places this provider in the 65th percentile of 447 gastroenterology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 11 | $74,927 |
| Mesalamine | 12 | $8,512 |
| Sucralfate | 26 | $4,159 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 45 | $2,906 |
| Omeprazole | 63 | $828 |
| Pantoprazole Sodium | 50 | $714 |
| Dicyclomine Hcl | 20 | $226 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Federal Way
- Kevin LeungFederal Way$359K
- Kris KowdleySeattle$5.9M
- Michael ChioreanIssaquah$3.9M
- Scott LeeSeattle$3.7M
- Timothy ZismanSeattle$3.3M
- William HoldermanTacoma$3.1M
- James LordSeattle$1.9M
- Charles LandisSeattle$1.7M
- Robert WohlmanBellevue$1.5M
- Asma SiddiqueSeattle$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.